Moberg Pharma: Sweden also approved - Redeye

Redeye sees the approval in the Swedish market as the most important in the short perspective as the Swedish market is the first launch market and the base for the first sales during 2024e and 2025e. The fact that the approval arrives so soon after the EU recommendations are favorable for the product launch into the high season in spring of 2024e.

Länk till analysen i sin helhet: https://www.redeye.se/research/927336/moberg-pharma-sweden-also-approved?utm_source=finwire&utm_medium=RSS